PINATITIGIL ng Food and Drugs Administration (FDA) ang mga online selling platform na Shopee Philippines at Lazada Philippines sa pagbebenta ng mga gamot.
Sa isang kalatas, sinabi ng FDA na isinilbi at ipinatupad na ng kanilang Regulatory Enforcement Unit ang Summons with Preventive Measure Order (SPMO) na nag-aatas sa Shopee at Lazada na agarang itigil ang online selling at offering ng drug products hanggang hindi pa sila nakakakuha ng kaukulang License to Operate (LTO) mula sa FDA.
Inatasan din ang mga ito na mahigpit na tumalima sa inisyu nilang Advisory No. 2019-154 noong Hunyo 11, na nagbabala sa publiko laban sa panganib na maaaring idulot ng internet sales ng mga gamot, gaya ng antibiotics at steroids.
“In line with this (advisory), the FDA strengthens the enforcement on the online selling of health products. Major online selling platforms, such as Shopee Philippines and Lazada Philippines, are strictly mandated to observe compliance in the said Advisory,” anang FDA.
“The FDA, through the Regulatory Enforcement Unit, served and implemented Summons with Preventive Measure Order (SPMO) directing Shopee Philippines and Lazada Philippines under pain of direct or indirect contempt and/or other administrative sanctions, to immediately CEASE AND DESIST from further online selling and offering for sale drug products until it has secured the appropriate License to Operate (LTO) from the FDA,” dagdag pa nito.
Ayon sa FDA, pursigido silang ipatupad ang batas laban sa online selling ng mga drug product dahil maglalagay umano ito sa panganib sa buhay ng publiko.
“Likewise, the FDA assures the public of the continued implementation and monitoring of an effective drug regulatory system responsive to the country’s health needs and problem. The FDA warns the public to exercise extreme caution and to avoid purchasing/consuming health products offered for sale online,” babala pa ng FDA.
Hinikayat din ng ahensiya ang publiko na kaagad na i-report sa kanilang tanggapan kung may nalalaman silang unauthorized sale o distribusyon ng drug products sa [email protected] o sa online reporting facility na eREPORT, sa www.fda.gov.ph/ereport, o ‘di kaya’y itawag sa Center for Drug Regulation and Research sa mga numerong (02) 809-5596. ANA ROSARIO HERNANDEZ
Comments are closed.